|Systematic (IUPAC) name|
|Mol. mass||522.586 g/mol|
|(what is this?)|
Remogliflozin etabonate (INN/USAN) is a proposed drug for the treatment of type 2 diabetes being investigated by GlaxoSmithKline. Remogliflozin is now being developed by BHV Pharma.
Method of action
Remogliflozin inhibits the sodium-glucose transport proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
- Statement on a nonproprietory name adopted by the USAN council
- Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M (June 2008). "Remogliflozin etabonate, in a Novel Category of Selective Low-Affinity / High-Capacity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models". J. Pharmacol. Exp. Ther. 327 (1): 268–276. doi:10.1124/jpet.108.140210. PMID 18583547.
- Prous Science: Molecule of the Month November 2007
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|